title: Serotonergic targets in depression.
abstract: Serotonin reuptake inhibitors have proved to be a very effective treatment for depression and have strengthened the hypothesis that impaired 5-hydroxytryptamine (5-HT) neurotransmission may contribute to the underlying cause of depressive disorders. Extensive research has been carried out to investigate other 5-HT targets associated with the disease and studies involving combination treatments with selective serotonin reuptake inhibitors and 5-HT(1A) receptor ligands are currently being carried out in the clinic. Whether other 5-HT receptor subtypes are involved in the aetiology of depression remains to be seen.
authors.affiliation: Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline, Third Avenue, Harlow, Essex CM19 5AW, UK.
authors.forename: Derek N
authors.initials: DN
authors.lastname: Middlemiss
authors.forename: Gary W
authors.initials: GW
authors.lastname: Price
authors.forename: Jeannette M
authors.initials: JM
authors.lastname: Watson
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000008:administration & dosage*; D003863:Depression / Q000188:drug therapy* / Q000378:metabolism*; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D011985:Receptors, Serotonin / Q000502:physiology
chemical_list: D000928:Antidepressive Agents; D011985:Receptors, Serotonin